Sonoma Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) on January 2, 2026. The report discloses the completion of the company's annual equity grant program to employees and executive officers.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on compensatory arrangements and does not contain financial performance data.
Material Changes and Equity Grants
On January 2, 2026, the company executed annual equity grants with the following terms:
- Non-Employee Directors: Each received 10,000 stock options.
- Option Terms: Exercise price set at $3.68 per share (closing price on Jan 2, 2026). Options vest in three equal tranches over three years.
- Executive Officers (RSUs):
- Amy Trombly (CEO): 10,000 Restricted Stock Units (RSUs).
- Jerry Dvonch (CFO): 5,000 Restricted Stock Units (RSUs).
- RSU Vesting: Vests on the third anniversary of the grant date, upon a change of control, or as specified in employment agreements.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, outlook, management commentary on operations, or specific risk factors beyond the standard disclosure of the equity grant terms.
Key Facts for Investor Verification
- Verify the total number of shares authorized under the company's equity incentive plan to ensure sufficient capacity for these grants.
- Confirm the dilution impact of the 15,000 RSUs and director options on existing shareholders.
- Review the specific vesting acceleration clauses related to "change of control" in the executive employment agreements.
- Monitor the stock price relative to the $3.68 exercise price to assess the immediate intrinsic value of the director options.